Curis Inc (CRIS : NASDAQ)
Common Stock
$0.55
USD
+0.09 (20.81%)
Last updated: 2026-10-29
Follow CRIS
CRIS
Curis Inc
WealthAwesomePerformance
1 Day
+20.81%
1 Week
+37.13%
1 Month
-33.84%
YTD
-93.31%
Key Statistics
Market Cap
$1.33M
52W High
$31.80
52W Low
$0.33
P/E Ratio
0.42
50 Day MA
$0.94
200 Day MA
$9.13
Beta
3.10
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/29/2026 | $0.46 | $0.67 | $0.45 | $0.55 | $0.55 | 6,201,062 |
| 10/28/2026 | $0.41 | $0.45 | $0.40 | $0.45 | $0.45 | 250,766 |
| 10/27/2026 | $0.38 | $0.41 | $0.37 | $0.40 | $0.40 | 227,341 |
| 10/26/2026 | $0.41 | $0.41 | $0.36 | $0.38 | $0.38 | 315,490 |
| 10/23/2026 | $0.41 | $0.42 | $0.38 | $0.39 | $0.39 | 66,900 |
| 10/22/2026 | $0.40 | $0.41 | $0.38 | $0.40 | $0.40 | 157,900 |
| 10/21/2026 | $0.41 | $0.41 | $0.39 | $0.39 | $0.39 | 95,800 |
| 10/20/2026 | $0.37 | $0.41 | $0.37 | $0.40 | $0.40 | 217,100 |
| 10/19/2026 | $0.41 | $0.43 | $0.36 | $0.38 | $0.38 | 226,454 |
| 10/16/2026 | $0.45 | $0.45 | $0.33 | $0.41 | $0.41 | 1,328,500 |
Analyst Price Targets
Based on 4 analysts covering CRIS · as of Oct 5, 2026
Wall Street analysts forecast CRIS stock price to rise 7678.8% over the next 12 months.
Consensus
Strong Buy4.75 / 5.00
Avg. Target
US$42.67
+7678.8% Upside
Current Price
US$0.55
Last close
Analyst Breakdown (4 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRIS's historical volatility
30-Day Vol
117.1%
Annualized
90-Day Vol
183.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$0.46
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$0.52 | US$0.35 – US$0.77 |
| 60 trading days | US$0.49 | US$0.28 – US$0.86 |
| 90 trading days | US$0.46 | US$0.23 – US$0.92 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Financials
- Revenue (TTM)
- $4.31M
- EBITDA
- $-35.87M
- Profit Margin
- 0.00%
- ROE (TTM)
- -693.93%
- EPS (Diluted)
- 1.32
- Book Value
- 2.41
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About CRIS.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| PCLA | PicoCELA Inc. American Depositary Shares | $11.10 | +86.09% |
| GENVR | Gen Digital Inc. Contingent Value Rights | $1.75 | +65.09% |
| NCPL | Netcapital Inc | $1.78 | +61.82% |
| INLF | INLIF LIMITED Ordinary Shares | $0.27 | +47.22% |
| XCH | XCHG Limited American Depositary Share | $3.46 | +41.80% |
| AMPGZ | Amplitech Group, Inc. Series B Right | $0.05 | +40.80% |
| SGLY | Singularity Future Technology Ltd | $0.50 | +40.17% |
| JFIN | Jiayin Group Inc | $1.72 | +37.60% |